Overgrowth shows no link to intestinal damage, yet strikes hardest in refractory cases.
Among the many burdens carried by those with celiac disease, a hidden microbial imbalance may be quietly compounding their suffering. A large study published in Nature finds that small intestinal bacterial overgrowth affects anywhere from one in six to nearly half of celiac patients depending on how it is measured—and in those whose disease resists treatment, the rates climb far higher. Strikingly, the severity of intestinal damage offers no reliable warning: overgrowth appears indifferent to how wounded the gut lining looks under a microscope, suggesting that the relationship between celiac disease and the microbial world is more intricate than medicine has assumed.
- Nearly half of celiac patients may harbor bacterial overgrowth in their small intestine—a prevalence that doubles or triples in those whose symptoms persist despite a strict gluten-free diet.
- The finding disrupts a tidy assumption: intestinal damage scores do not predict who will develop overgrowth, meaning clinicians cannot rely on disease severity as a screening filter.
- Decades of inconsistent research—with prevalence estimates swinging from 2 to 50 percent—are now partly explained by the fact that different studies were testing very different patient populations and using different diagnostic thresholds.
- Antibiotic treatment offers a compelling path forward, with one small study reporting complete symptom resolution in all treated patients and a meta-analysis showing meaningful improvement in 96 percent of cases.
- The study's own design introduces caution: drawn from a tertiary care center full of complicated cases, its numbers likely overstate how common overgrowth is in the broader celiac population.
A study published in Nature has found that bacterial overgrowth in the small intestine is far more prevalent among celiac disease patients than previously recognized—and that it strikes hardest in those already hardest to treat.
Researchers examined 256 celiac patients using direct sampling of intestinal fluid. At the traditional diagnostic threshold, 17.6 percent tested positive for small intestinal bacterial overgrowth. Applying a lower, more recently validated threshold pushed that figure to 49.6 percent. In patients with refractory celiac disease—those whose symptoms persist despite strict adherence to a gluten-free diet—rates reached 78.9 percent. A smaller group tested via breath analysis showed a 23.1 percent positivity rate, driven entirely by intestinal methanogen overgrowth. Fungal overgrowth was rare, appearing in just 4.3 percent of patients, though the researchers suspect this is an undercount given their lab methods favored bacterial detection.
The most counterintuitive finding was an absence: bacterial overgrowth bore no relationship to the degree of intestinal damage visible under the microscope. A patient with severe mucosal injury was no more likely to harbor overgrowth than one with mild changes. This decouples two things clinicians might have assumed traveled together, and it points toward a more layered interaction between celiac disease and the gut's microbial ecosystem.
The bacteria identified—predominantly Klebsiella and Escherichia species from the Enterobacteriaceae family—are familiar from other overgrowth conditions and are known to drive symptoms and metabolic disruption. The clinical message the researchers draw is direct: symptomatic celiac patients should be tested for overgrowth regardless of where they appear to stand in their disease course, because the intestinal lining's appearance offers no reliable clue. Prior research supports acting on a positive result—a meta-analysis of four studies found that 96 percent of celiac patients treated with antibiotics showed significant symptom improvement, and breath tests normalized in every patient retested after treatment.
The study carries real limitations. It was retrospective, drawing from a tertiary center that attracts complicated cases, which likely inflates its prevalence estimates. Treatment outcomes were not tracked, and the two diagnostic methods showed poor agreement in the small group that underwent both. The researchers call for prospective studies that follow patients from diagnosis, settle the question of which test is most reliable, and measure real-world treatment outcomes.
A large study published in Nature reveals that microbial overgrowth in the small intestine is far more common among celiac disease patients than previously understood, affecting nearly half of those tested—and occurring at dramatically higher rates in the most difficult-to-treat cases.
Researchers analyzed 256 celiac patients who underwent testing for small intestinal bacterial overgrowth, or SIBO, using direct sampling of intestinal fluid. Using the traditional diagnostic threshold, they found SIBO in 17.6 percent of patients. But when they applied a lower bacterial count threshold that recent research has validated as more clinically meaningful, the prevalence jumped to 49.6 percent. In patients with refractory celiac disease—those whose symptoms persist despite strict adherence to a gluten-free diet—the rates were even starker: 36.8 percent at the higher threshold and 78.9 percent at the lower one. A smaller group of 39 patients underwent breath testing, a less invasive diagnostic method, and 23.1 percent tested positive, all due to intestinal methanogen overgrowth, a specific type of microbial imbalance.
What surprised the researchers was what they did not find. The presence of bacterial overgrowth showed no correlation with the severity of intestinal damage visible under the microscope—measured by what pathologists call Marsh scores. This suggests that a patient with severe celiac damage is not necessarily more likely to harbor bacterial overgrowth than someone with mild changes. The finding upends a simple assumption: that worse disease means worse dysbiosis. Instead, it points toward a more complex relationship between celiac disease and the microbial ecosystem of the gut.
Fungal overgrowth was rare, appearing in only 4.3 percent of patients, usually alongside bacterial overgrowth. The researchers acknowledged this figure likely underestimates the true prevalence, since their lab culture methods were optimized for bacteria and would miss fungi unless they grew aggressively enough to be noticed incidentally.
This is the largest study to date examining bacterial overgrowth specifically in celiac patients. Previous research had produced wildly inconsistent results—prevalence estimates ranging from 2 to 50 percent depending on the study population and testing method. The new work helps explain that variability: different studies had enrolled different patient populations, from those in complete remission to those with active, unresponsive disease. The researchers note their own cohort likely skews toward complicated cases, since their tertiary care center draws patients with persistent symptoms and treatment-resistant disease, which may inflate their prevalence estimates.
The specific bacteria identified in overgrowth cases matched patterns seen in other dysbiosis research: an excess of Enterobacteriaceae family members, particularly Klebsiella and Escherichia species. These organisms have been implicated in causing symptoms and metabolic disruption in other conditions characterized by bacterial overgrowth.
The clinical implications are significant. Because bacterial overgrowth showed no relationship to how damaged the intestinal lining appeared, the researchers argue that celiac patients with ongoing symptoms should be tested for overgrowth regardless of their disease stage or how well their intestines appear to have healed. Prior studies have shown that treating bacterial overgrowth with antibiotics in celiac patients produces striking results: in one small prospective study, all ten patients with refractory celiac disease and confirmed overgrowth experienced complete symptom resolution after antibiotic treatment. A meta-analysis of four studies found that 96 percent of celiac patients treated for overgrowth showed significant symptom improvement, and in studies that repeated breath testing after treatment, 100 percent of tests normalized.
The researchers acknowledge significant limitations. This was a retrospective analysis of patients who were already being tested for overgrowth, introducing selection bias toward symptomatic individuals. The study did not track treatment responses, did not account for medications like proton pump inhibitors that might promote overgrowth, and did not control for other conditions that could contribute to dysbiosis. The two diagnostic methods—direct culture and breath testing—showed poor agreement in the small subset of patients who underwent both, raising questions about which approach is most reliable. Future research should prospectively track overgrowth from the moment of celiac diagnosis onward, determine which diagnostic method works best, and measure how often treatment actually resolves symptoms in real-world practice.
Citações Notáveis
SIBO testing should be considered among celiac disease patients at any point in their disease with ongoing symptoms— Study authors, Nature
In a prospective study of 15 patients with nonresponsive celiac disease, 10 had microbial overgrowth, and after antibiotic treatment, 100% had complete symptom resolution— Prior research cited in study
A Conversa do Hearth Outra perspectiva sobre a história
Why does bacterial overgrowth show up so much more often in refractory celiac disease than in regular celiac disease?
That's the question the researchers couldn't fully answer from this data. But the pattern suggests something interesting: maybe overgrowth isn't just a passive consequence of having celiac damage. If it were, you'd expect to see it correlate with how much intestinal damage is visible under the microscope—and it doesn't. So overgrowth might be either a separate problem that happens to occur alongside celiac disease, or it might be something that develops when the gut environment becomes chronically disrupted in ways that don't show up on a biopsy.
The study mentions that antibiotic treatment works really well for symptoms. Does that mean overgrowth is actually causing the symptoms in refractory cases?
That's tempting to conclude, but it's more complicated. The researchers found that two-thirds of refractory celiac patients with overgrowth also had another condition—microscopic colitis, or a rare lymphoma. So the overgrowth might be a marker of a more complicated gut situation rather than the root cause itself. It's like finding mold in a house with a leaky roof—treating the mold helps, but you still need to fix the roof.
Why did all the positive breath tests show methane instead of hydrogen?
Methane production is associated with slow gut movement and constipation. That's interesting because celiac patients often develop constipation after starting a gluten-free diet, even though the disease itself is usually associated with diarrhea. So there might be a subset of celiac patients whose guts slow down over time, creating conditions where methane-producing organisms thrive. But the researchers note they probably missed a lot of methane cases entirely, because their main diagnostic method—direct sampling—doesn't easily detect methanogens.
The study mentions contamination as a problem with the cultures. How much does that undermine the findings?
It's a real concern. One in five samples was contaminated with mouth bacteria, and when researchers compared culture results to breath tests, they disagreed 36 percent of the time. So some of those positive cultures might be false positives. But even accounting for that, the prevalence is still remarkably high, especially in refractory disease. The breath test results—which are harder to contaminate—still showed overgrowth in nearly a quarter of patients tested.
What should a celiac patient with ongoing symptoms do with this information?
The researchers' message is clear: if you have celiac disease and persistent symptoms despite following a gluten-free diet, ask your doctor about testing for overgrowth. Don't assume your symptoms mean your celiac disease is still active or that your intestines are still damaged. It might be a separate problem that responds well to antibiotics. The catch is that testing isn't standardized yet, and the two methods don't always agree, so you might need to try more than one approach.